Skip to main content
. 2022 Feb 17;61(11):4384–4396. doi: 10.1093/rheumatology/keac079

Table 3.

Associations between NVC and novel severe organ involvement/progression during follow-up (0–24 months)—univariable logistic regression

Novel severe organ involvement and/or progression (0–24 months) QUANTITATIVE ASSESSMENT
QUALITATIVE ASSESSMENT
Capillary density
Capillary dimension
Capillary morphology
Micro-haemorrhages
Presence of scleroderma pattern
Presence of ‘severe’ NVC patternsa
OR P-value OR P-value OR P-value OR P-value OR P-value OR P-value
(95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI)
Overall future organ involvement, (n = 257) 0.76 (0.65, 0.88) <0.001 1.25 (0.77, 2.01) 0.372 1.33 (0.52, 3.13) 0.533 1.01 (0.63, 1.62) 0.955 1.34 (0.81, 2.21) 0.251 2.136 (1.33, 3.44) 0.002
Peripheral vascular, (n = 111) 0.68 (0.57, 0.80) <0.001 1.15 (0.70, 1.92) 0.585 0.58 (0.22, 1.54) 0.271 0.72 (0.44, 1.16) 0.170 1.26 (0.74, 2.18) 0.399 1.82 (1.12, 2.98) 0.015
Pulmonary
Structural
 New ILD, (n = 19) 0.78 (0.56, 1.06) 0.110 0.41 (0.16, 1.06) 0.065 2.86 (0.37, 368.71) 0.393 0.92 (0.36, 2.44) 0.865 0.48 (0.19, 1.27) 0.135 0.65 (0.25, 1.65) 0.355
 Progression of known ILD, (n = 67) 0.85 (0.70, 1.02) 0.084 0.85 (0.48, 1.53) 0.586 2.75 (0.76, 17.70) 0.136 0.74 (0.42, 1.30) 0.295 0.84 (0.46, 1.57) 0.578 0.81 (0.47, 1.43) 0.470
Vascular
 New PH, (n = 45) 0.87 (0.70, 1.07) 0.201 0.60 (0.31, 1.15) 0.122 1.54 (0.42, 9.94) 0.552 0.42 (0.22, 0.80) 0.008 0.88 (0.45, 1.83) 0.728 1.46 (0.76, 2.93) 0.260
 New PAH, (n = 5) 0.82 (0.44, 1.46) 0.521 1.90 (0.28, 37.34) 0.547 0.77 (0.08, 102.11) 0.864 0.95 (0.16, 7.33) 0.959 2.26 (0.04, 22.71) 0.365 3.01 (0.44, 59.17) 0.283
Skin progression, (n = 140) 0.97 (0.83, 1.14) 0.729 1.46 (0.86, 2.47) 0.165 1.00 (0.232, 2.97) 1.000 1.31 (0.78, 2.20) 0.308 1.63 (0.93, 2.85) 0.087 1.71 (1.02, 2.87) 0.042
Death, (n = 5) 0.82 (0.43, 1.44) 0.501 0.71 (0.12, 5.48) 0.718 0.28 (0.04, 5.64) 0.327 0.44 (0.06, 2.66) 0.359 1.50 (0.22, 29.60) 0.707 6.86 (0.72, 912.33) 0.104
Heart, (n = 18) 0.98 (0.72, 1.33) 0.917 0.818 (0.31, 2.30) 0.692 0.50 (0.12, 3.36) 0.417 1.31 (0.49, 3.89) 0.595 1.02 (0.38, 3.12) 0.969 1.01 (0.39, 2.75) 0.977
Gastrointestinal tract, (n = 5) 1.56 (0.91, 2.72) 0.106 1.92 (0.28, 37.75) 0.540 0.76 (0.08, 101.70) 0.862 0.45 (0.07, 2.36) 0.339 1.49 (0.22, 29.33) 0.714 0.18 (0.01, 1.26) 0.088
SRC, (n = 5) 0.98 (0.54, 1.69) 0.944 1.94 (0.28, 38.16) 0.533 0.76 (0.08, 101.29) 0.860 0.90 (0.17, 5.44) 0.894 1.51 (0.22, 29.71) 0.705 2.29 (0.42, 23.08) 0.355
Musculoskeletal, (n = 59) 0.98 (0.82, 1.18) 0.866 0.84 (0.47, 1.53) 0.560 4.50 (0.90, 81.92) 0.072 0.84 (0.47, 1.51) 0.552 1.02 (0.55, 1.98) 0.948 1.12 (0.63, 2.02) 0.705

Underlined text: Firth log used. Bold text: Statistically significant finding (P < 0.05). a‘Active’ and ‘late’ NVC patterns were considered ‘severe’ NVC patterns. ILD: interstitial lung disease; NVC: nailfold videocapillaroscopy; OR: odds ratio; PAH: pulmonary arterial hypertension; PH: pulmonary hypertension; SRC: scleroderma renal crisis.